Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during

IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcr

Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the

Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C

Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal mela

Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperf

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the disco

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

 IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the disc

Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUT

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

IDEAYA Biosciences is transitioning into a commercial oncology platform, leveraging darovasertib's r

Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-

IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Ph

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the ana

Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) m

SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative

IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma

SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA),

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and

SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal me

SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) t

U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak e

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswir

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) tod

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential b

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

Key Findings from OptimUM-02Primary endpoint (Phase 2 portion): progression free survival by BICRThe

Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.11) per share which missed the ana

- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today annou

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral a

Wells Fargo analyst Eva Fortea Verdejo maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweig

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and